| Literature DB >> 21922647 |
Malcolm A Smith1, Richard Gorlick, E Anders Kolb, Richard Lock, Hernan Carol, John M Maris, Stephen T Keir, Christopher L Morton, C Patrick Reynolds, Min H Kang, Janine Arts, Tarig Bashir, Michel Janicot, Raushan T Kurmasheva, Peter J Houghton.
Abstract
JNJ-26854165 was originally developed as an activator of p53 capable of inducing apoptosis in cancer cell lines. In vitro, JNJ-26854165 demonstrated cytotoxic activity. The ALL cell line panel had a significantly lower median IC(50) (0.85 µM) than the remaining cell lines. In vivo JNJ-26854165 induced significant differences in EFS distribution compared to control in 18 of 37 solid tumors and in 5 of 7 of the evaluable ALL xenografts. Objective responses were observed in 4 of 37 solid tumor xenografts, and 2 of 7 ALL xenografts achieved PR or CR. Responses were noted in xenografts with both mutant and wild-type p53.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21922647 PMCID： PMC4504194 DOI： 10.1002/pbc.23319
Source DB: PubMed Journal: Pediatr Blood Cancer ISSN： 1545-5009 Impact factor: 3.167